These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26419328)

  • 21. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.
    Kim DH; Chung HJ; Bleys J; Ghohestani RF
    PLoS Negl Trop Dis; 2009; 3(2):e381. PubMed ID: 19221595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fractional CO(2) laser-assisted drug delivery.
    Haedersdal M; Sakamoto FH; Farinelli WA; Doukas AG; Tam J; Anderson RR
    Lasers Surg Med; 2010 Feb; 42(2):113-22. PubMed ID: 20166154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Occlusive paromomycin for cutaneous leishmaniasis.
    Bryceson AD
    Lancet; 1997 May; 349(9063):1477. PubMed ID: 9164342
    [No Abstract]   [Full Text] [Related]  

  • 24. Unsuccessful treatment of cutaneous leishmaniasis by Leishmania infantum with topical paromomycin.
    Veraldi S; Benzecry Mancin V; Faraci AG; Nazzaro G
    Int J Dermatol; 2020 Jul; 59(7):e251-e252. PubMed ID: 31975375
    [No Abstract]   [Full Text] [Related]  

  • 25. Ablative Fractional Resurfacing for Chronic Wounds from Traumatic Scarring: A Case Report and Literature Review.
    Mehrabi JN; Kelly KM
    J Drugs Dermatol; 2020 Nov; 19(11):1112-1115. PubMed ID: 33196743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leishmaniasis chemotherapy--challenges and opportunities.
    Croft SL; Olliaro P
    Clin Microbiol Infect; 2011 Oct; 17(10):1478-83. PubMed ID: 21933306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editorial commentary: local treatments for cutaneous leishmaniasis.
    Bailey MS
    Clin Infect Dis; 2013 Aug; 57(3):381-3. PubMed ID: 23633110
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
    Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R
    Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
    Shazad B; Abbaszadeh B; Khamesipour A
    Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug delivery systems for the topical treatment of cutaneous leishmaniasis.
    Carneiro G; Aguiar MG; Fernandes AP; Ferreira LA
    Expert Opin Drug Deliv; 2012 Sep; 9(9):1083-97. PubMed ID: 22724539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Cutaneous Leishmaniasis in a Nonendemic Country: A Case Series of Children in Australia.
    Hill N; Irwin A; Graham N; Leung C; Francis JR; Wall N; Nourse C
    Pediatr Infect Dis J; 2022 Apr; 41(4):e177-e181. PubMed ID: 34966136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Successful topical treatment of chronic cutaneous leishmaniasis with paromomycin sulfate (15%) and methylbenzethonium chloride (12%)].
    Schallreuter KU; Lemke KR
    Hautarzt; 1994 Nov; 45(11):783-6. PubMed ID: 7822205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ablative fractional laser resurfacing helps treat restrictive pediatric scar contractures.
    Krakowski AC; Goldenberg A; Eichenfield LF; Murray JP; Shumaker PR
    Pediatrics; 2014 Dec; 134(6):e1700-5. PubMed ID: 25367535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A Critically Appraised Topic.
    Burden-Teh E; Wootton CI; Williams HC
    Br J Dermatol; 2015 Apr; 172(4):861-6. PubMed ID: 25354137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current scenario of drug development for leishmaniasis.
    Croft SL; Seifert K; Yardley V
    Indian J Med Res; 2006 Mar; 123(3):399-410. PubMed ID: 16778319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous leishmaniasis.
    Bailey MS; Lockwood DN
    Clin Dermatol; 2007; 25(2):203-11. PubMed ID: 17350500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple-combination therapy for cutaneous leishmaniasis using detergent-free, hyaluronate-coated elastic nanovesicles.
    Iqbal K; Khalid S; McElroy CA; Adnan M; Khan GM; Dar MJ
    Nanomedicine (Lond); 2022 Aug; 17(20):1429-1447. PubMed ID: 36301316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment of atrophic postoperative and traumatic scarring with carbon dioxide ablative fractional resurfacing: quantitative volumetric scar improvement.
    Weiss ET; Chapas A; Brightman L; Hunzeker C; Hale EK; Karen JK; Bernstein L; Geronemus RG
    Arch Dermatol; 2010 Feb; 146(2):133-40. PubMed ID: 20157023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leishmaniasis: an update of current pharmacotherapy.
    Sundar S; Chakravarty J
    Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.